Regardless of the presence or absence of HER‐2 amplification, deletion, functionally important somatic mutations, and downregulation of the FOXP3 gene were frequently observed in human breast cancer samples and significantly linked with HER‐2/ErbB2 overexpression. This evidence concerns the gene ERBB2 and breast cancer.